SciELO - Scientific Electronic Library Online

 
vol.2 número4Obesidad central y regresión de hipertrofia ventricular izquierdaEstatinas en insuficiencia cardíaca: "dar o no dar" índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Bookmark


Insuficiencia cardíaca

versión On-line ISSN 1852-3862

Resumen

LEMA, Luis R. Clinical experience with PDE-5 inhibitors. Insuf. card. [online]. 2007, vol.2, n.4, pp. 163-167. ISSN 1852-3862.

Pulmonary hypertension is a serious disease of various origins. In the last ten years we have witnessed tremendous advancements in our understanding of the pathogenesis of pulmonary arterial hypertension. Several of these new insights have led to the development and clinical application of novel treatments for this devasting disease. Nitric oxide-a potent vasodilator- is a key player of pulmonary vasoregulation with cGMP as a second messenger. The effects of cGMP are limited by enzymatic degradation through phosphodiesterases (PDEs). Sildenafil a highly selective inhibitor of PDEs 5 improved pulmonary hemodynamics and exercise capacity for patients with pulmonary arterial hypertension as monotherapy and/or in combination with other vasodilators. This review article summarizes the pharmacology, clinical efficacy and safety of sildenafil and others PDEs5 inhibitors for the treatment of pulmonary arterial hypertension.

        · resumen en Español | Portugués     · texto en Español     · pdf en Español